6D88

Tubulin-RB3_SLD-TTL in complex with compound 13f

6D88 の概要

• エントリーDOI: 10.2210/pdb6d88/pdb
• 分子名称: Tubulin alpha-1B chain, [2-(1H-indol-3-yl)-1H-imidazol-4-yl](8-methoxy-1,4-benzodioxin-6-yl)methanone, PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER, ... (12 entities in total)
• 機能のキーワード: microtubule inhibitor, colchicine, cancer, cell cycle
• 由来する生物種: Rattus norvegicus (Rat); 詳細
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 265033.22

構造登録者

Kumar, G.,Wang, Y.,Li, W.,White, S.W. (登録日: 2018-04-26, 公開日: 2018-09-12, 最終更新日: 2024-03-13)

主引用文献

Wang, Q.,Arnst, K.E.,Wang, Y.,Kumar, G.,Ma, D.,Chen, H.,Wu, Z.,Yang, J.,White, S.W.,Miller, D.D.,Li, W.
Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.
J. Med. Chem., 61:7877-7891, 2018

PubMed Abstract: Colchicine binding site inhibitors (CBSIs) hold great potential in developing new generations of antimitotic drugs. Unlike existing tubulin inhibitors such as paclitaxel, they are generally much less susceptible to resistance caused by the overexpression of drug efflux pumps. The 3,4,5-trimethoxyphenyl (TMP) moiety is a critical component present in many CBSIs, playing an important role in maintaining suitable molecular conformations of CBSIs and contributing to their high binding affinities to tubulin. Previously reported modifications to the TMP moiety in a variety of scaffolds of CBSIs have usually resulted in reduced antiproliferative potency. We previously reported a potent CBSI, VERU-111, that also contains the TMP moiety. Herein, we report the discovery of a VERU-111 analogue 13f that is significantly more potent than VERU-111. The X-ray crystal structure of 13f in complex with tubulin confirms its direct binding to the colchicine site. In addition, 13f exhibited a strong inhibitory effect on tumor growth in vivo.

PubMed: 30122035
DOI: 10.1021/acs.jmedchem.8b00827

実験手法

X-RAY DIFFRACTION (2.853 Å)